Who are Tesomet "Low dose" in fasted condition's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tesomet "High dose" in fed condition.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tesomet-low-dose-in-fasted-condition.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tesomet "Low dose" in fasted condition — Competitive Intelligence Brief

Tesomet "Low dose" in fasted condition (Tesomet "Low dose" in fasted condition) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoamine reuptake inhibitor + biguanide combination. Area: Endocrinology / Obesity.

marketed Monoamine reuptake inhibitor + biguanide combination Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase Endocrinology / Obesity Small molecule Live · refreshed every 30 min

Target snapshot

Tesomet "Low dose" in fasted condition (Tesomet "Low dose" in fasted condition) — Saniona. Tesomet is a combination of tesofensine (a monoamine reuptake inhibitor) and metformin that promotes weight loss by increasing satiety and energy expenditure while improving metabolic control.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tesomet "Low dose" in fasted condition TARGET	Tesomet "Low dose" in fasted condition	Saniona	marketed	Monoamine reuptake inhibitor + biguanide combination	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase
Tesomet "High dose" in fed condition	Tesomet "High dose" in fed condition	Saniona	marketed	Monoamine reuptake inhibitor + biguanide combination	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoamine reuptake inhibitor + biguanide combination class)

Saniona · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tesomet "Low dose" in fasted condition — Competitive Intelligence Brief. https://druglandscape.com/ci/tesomet-low-dose-in-fasted-condition. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab